z-logo
Premium
Oligometastatic squamous cell carcinoma of the head and neck treated with stereotactic body ablative radiotherapy: Single‐institution outcomes
Author(s) -
Bates James E.,
De Leo Alexandra N.,
Morris Christopher G.,
Amdur Robert J.,
Dagan Roi
Publication year - 2019
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.25695
Subject(s) - medicine , ablative case , head and neck squamous cell carcinoma , radiosurgery , radiation therapy , oncology , overall survival , head and neck , head and neck cancer , radiology , surgery
Purpose/Objectives We analyzed outcomes after stereotactic ablative body radiotherapy for oligometastatic (1‐5 metastatic foci) head‐and‐neck squamous cell carcinoma (OM‐HNSCC). Materials/Methods We reviewed patients treated between 2012 and 2016. Endpoints included overall survival (OS), distant progression, and treated‐metastasis local control (TM‐LC). Results We analyzed 27 patients with 60 primarily metachronous metastases (81.5%). Median follow‐up was 1.6 years (0.2‐5.2). Median time from diagnosis to treatment was 1.1 years (0.08‐8.5). Overall, 44.4% had solitary, 44.4% had 2‐3, and 11.1% had >3 metastases; most metastases were in the lung (44 of 60 metastases). Median OS was 1.9 years; at 1 and 2 years, 78% and 43% were alive (14% without disease progression). Median time to progression was 0.5 years. The 1‐year and 2‐year TM‐LC rates were 75% and 57%. Conclusions OS is encouraging and disease‐free survival remains poor; nevertheless, patients with OM‐HNSCC may represent a more favorable subset of patients with metastatic HNSCC.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here